ArticleTherapeutic advances in medical oncology2025

Impact of claudin 18.2 expression on treatment outcomes of first-line immunochemotherapy in patients with HER2-negative, proficient MMR, PD-L1 CPS ⩾1 metastatic gastric/gastroesophageal junction cancer.

Fei Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.